CLINICAL TRIAL: TRIAL OF BETA BLOCKER THERAPY (ATENOLOL) VS ANGIOTENSIN II RECE

临床试验：β 受体阻滞剂治疗（阿替洛尔）对比血管紧张素 II RECE 的试验

• 批准号: 8174439
• 负责人: DAVID L RIMOIN
• 金额: $ 0.92万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174439
• 关键词: Adrenergic beta-Antagonists; Angiotensin Receptor; Angiotensins; Aortic Valve Insufficiency; Atenolol; Clinical Trials; Clinical Trials Design; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Growth; Individual; Institution; Marfan Syndrome; Patients; Phase; Randomized; Research; Research Personnel; Resources; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase III, randomized, multi-center trial designed to compare the effect of beta-blocker therapy to that of angiotensin receptor blocker therapy on rate of change in aortic growth and progression of aortic regurgitation in individuals with Marfan Syndrome. Patients are followed for three years after randomization.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项 III 期、随机、多中心试验，旨在比较 β 受体阻滞剂治疗与血管紧张素受体阻滞剂治疗对马凡综合征患者主动脉生长变化率和主动脉瓣反流进展的影响。随机分组后对患者进行三年随访。